Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas

OBJECTIVE: Interferon has antiproliferative and antiangiogenic properties. We sought to evaluate preliminary efficacy and determine the recommended phase II dose (RP2D) for pegylated interferon-α-2b (PI) in patients with unresectable progressive or symptomatic plexiform neurofibromas (PN). METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jakacki, R.I., Dombi, E., Potter, D.M., Goldman, S., Allen, J.C., Pollack, I.F., Widemann, B.C.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3034394/
https://ncbi.nlm.nih.gov/pubmed/21242495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318207b031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados